Harmony Biosciences Holdings, Inc. reports results for the quarter ended September 30 - Earnings Summary

• Harmony Biosciences Holdings, Inc. reported quarterly adjusted earnings of 81 cents​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of 87 cents. The mean expectation of twelve analysts for the quarter was for earnings of $1.14 per share. Wall Street expected results to range from 86 cents to $1.54 per share.

• Revenue rose 12.3% to $268.92 million from a year ago; analysts expected $273.08 million.

• Harmony Biosciences Holdings, Inc.'s reported EPS for the quarter was 81 cents​.

• The company reported quarterly net income of $48.2 million.

• Harmony Biosciences Holdings, Inc. shares had fallen by 5.7% this quarter and lost 1.1% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 2.3% in the last three months.​

• In the last 30 days, two analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 3 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for Harmony Biosciences Holdings, Inc. is $49.50, about 25.2% above its last closing price of $37.02

This summary was machine generated from LSEG data November 4 at 02:32 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)